Whalen Wealth Management Inc. Purchases New Shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Whalen Wealth Management Inc. acquired a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 26,292 shares of the company's stock, valued at approximately $404,000.

Other hedge funds have also recently modified their holdings of the company. Oarsman Capital Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $44,000. Compagnie Lombard Odier SCmA acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter worth approximately $54,000. Versant Capital Management Inc boosted its position in shares of Teva Pharmaceutical Industries by 437.8% during the 1st quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock worth $81,000 after purchasing an additional 4,312 shares during the period. Finally, IFP Advisors Inc boosted its position in shares of Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after purchasing an additional 1,960 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Analyst Ratings Changes

TEVA has been the subject of several research analyst reports. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 price target on the stock. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target for the company. Finally, UBS Group lowered their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday. Nine analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of "Buy" and a consensus target price of $24.00.

Insider Buying and Selling

In other news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president now directly owns 9,989 shares of the company's stock, valued at approximately $170,012.78. The trade was a 38.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.49% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Down 2.3%

Shares of TEVA traded down $0.38 during mid-day trading on Thursday, reaching $16.62. The company's stock had a trading volume of 13,549,319 shares, compared to its average volume of 10,269,467. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80. The stock has a market cap of $19.06 billion, a PE ratio of -14.45, a price-to-earnings-growth ratio of 0.87 and a beta of 0.60. The company's 50 day moving average is $16.60 and its 200 day moving average is $17.41.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. During the same period in the prior year, the company posted $0.48 earnings per share. The firm's quarterly revenue was up 1.9% compared to the same quarter last year. Equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.